# Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)

> **NCT05395195** · PHASE3 · RECRUITING · sponsor: **Imperial College London** · enrollment: 504 (estimated)

## Conditions studied

- Encephalopathy
- Erythropoietin
- Newborn Asphyxia

## Interventions

- **DRUG:** Erythropoietin
- **OTHER:** Supportive neonatal intensive care

## Key facts

- **NCT ID:** NCT05395195
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-31
- **Primary completion:** 2024-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2024-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05395195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05395195, "Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05395195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*